July 28, 2017 4:14 AM ET


Company Overview of Ferring Holding SA

Company Overview

Ferring Holding SA, through its subsidiaries, develops, manufactures, and markets pharmaceutical products in the fields of reproductive health, urology, gastroenterology, endocrinology, and osteoarthritis. It offers MINIRIN for bedwetting in children and nocturia in adults; FIRMAGON for advanced hormone-dependent prostate cancer; and TESTIM for treating men suffering from low testosterone. The company also provides MENOPUR and BRAVELLE ovarian-stimulating treatments used in the preparation for in-vitro fertilization; TRACTOCILE to treat pre-term labor; ZOMACTON, a recombinant human growth hormone used to treat growth failure in children; PENTASA for the treatment of inflammatory bowel diseas...

Chemin de la Vergognausaz 50

Saint-Prex,  1162


Founded in 2000


41 58 301 00 00


41 58 301 00 10

Key Executives for Ferring Holding SA

Executive Chairman and Chief Executive Officer
Age: 66
Executive VP & CFO
President of the Executive Board and Chief Operating Officer
Age: 64
President of Ferring Pharmaceuticals Inc. and COO of Ferring Pharmaceuticals Inc.
Vice Chairman
Compensation as of Fiscal Year 2017.

Ferring Holding SA Key Developments

Ferring Holding SA Presents at Pre-Filled Syringes San Diego Summit, Jun-05-2017 through Jun-06-2017

Ferring Holding SA Presents at Pre-Filled Syringes San Diego Summit, Jun-05-2017 through Jun-06-2017. Venue: HYATT REGENCY MISSION BAY, 1441 Quivira Road, San Diego, California, United States. Presentation Date & Speakers: Jun-05-2017, Tina Rees, Associate Director - Human Factors. Jun-06-2017, Tina Rees, Associate Director - Human Factors.

Ferring Pharmaceuticals Announces Management Changes

Ferring Pharmaceuticals announced that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective July 1, 2017. Moorhead succeeds Peter Wilden. Following a three-month transition period, Moorhead will assume full responsibility for the Finance, Corporate Information Systems and Internal Audit functions of the global Ferring Group. Wilden will continue to represent Ferring on a number of additional Boards. Moorhead has 30 years' finance and business experience in the life sciences industry. For the past year, he has been a strategic advisor to executives and investors in biotech.

Targeted Immuno Therapies and Ferring Sign IBD Treatment Collaboration Agreement

Ferring (Switzerland) and Targeted Immuno Therapies have entered into a strategic collaboration agreement whereby the Swiss firm received the global rights, with the exception of China, to the discovery of a novel treatment for inflammatory bowel diseases (IBD), with the parties set to collaborate on the development of a technology created by the Swedish firm. As per the agreement, Ferring would finance further product development and clinical trial programmes.

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Activen SA Europe
AL-S Pharma AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ferring Holding SA, please visit www.ferring.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.